While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > BUSINESS
BUSINESS
- UCB, Otsuka to Apply for Domestic Approval of RA Drug in 2012
November 10, 2011
- Pharmaceutical Sales Up 0.5% in Bayer AG Jan-Sep Results
November 10, 2011
- Daiichi Sankyo Obtains Brazil Rights for OAB Treatment Uritos
November 10, 2011
- Nippon Shinyaku Increases Both Sales, Profits Driven by Growth of Vidaza
November 10, 2011
- Premium for New Drug Development Should Be Increased: Mr Miyoshi of IMS Japan
November 10, 2011
- Sanofi Expected to Overtake Pfizer as World’s Top Drug Maker in 2012: Evaluate Pharma
November 10, 2011
- Seikagaku to Conduct Add’l PIII Trial for Lumbar Disc Herniation Treatment SI-6603
November 10, 2011
- Toho HD’s Sales Increased to ¥2 Bil. in 1st-Half Driven by Dispensing Pharmacy Business
November 9, 2011
- Toho Holdings' Matsutani Says His Company Will Protect Its Own Prices
November 9, 2011
- Operating Profit Rate for Top-4 Wholesalers Slips to 0.39% in April-September
November 9, 2011
- Astellas, RIKEN to Explore, Jointly Develop Novel Drug Targets for AD
November 9, 2011
- Yakult, LivTech Enter into Option Agreement for Anti-Cancer Monoclonal Antibody Development Program
November 9, 2011
- Towa Pharmaceutical Developing Lipitor Generic Version OD Tablets
November 9, 2011
- Nihon Chouzai Planning to Open 150-200 Stores a Year: President Mitsuhara
November 9, 2011
- CMIC Reports Increases in Sales and Profits Driven by CRO Business
November 8, 2011
- Nichi-Iko to Change Company Structure to Strengthen Sales of Generic Drugs
November 8, 2011
- Kaken to Enhance Detailing Activities for GPs Aiming at Sales Expansion for Lipidil, Generics
November 8, 2011
- Towa Pharmaceutical’s New Business Plan is “Groundwork for Future Progress”
November 8, 2011
- Suzuken President Ota Says Wholesale Business Recovery Crucial
November 8, 2011
- Towa Apr-Sep Earnings Limited on Break in Impact of Premium Revision
November 8, 2011
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
The average gap between the NHI prices and market prices of listed medicines shrank in the latest survey conducted in…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…